undamentalytics Newsletter
Sign in

Charles River Laboratories cash flow statement

In fiscal 2025, Charles River Laboratories's operations generated $738m of cash; it spent $219m on capital projects, leaving free cash flow of $518m. It returned $361m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations216168207208209252307317318441481547761620684735738582
Depreciation and amortisation90948581979695127131162198235266304314362403298
Stock-based pay242622222531404444475756717472707183
Capital spending804349483957635582140141167229325319233219212
Free cash flow136125158160170195244262236301340380532295365502518371
Free cash flow after stock pay112100136139145164203218192254283324461221293432447288
Share buybacks463572846416612211712107141824413924119361324

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRL vs MTDCRL vs ILMNBRKR vs CRLCRL vs WAT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Charles River Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Charles River Laboratories.